Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer

被引：0
|
作者：
Danielsson, O. [1 ]
Dar, H. A. [1 ]
Nordenskjold, A. [2 ]
Tenorio, G. Perez [3 ,4 ]
Yau, C. [5 ]
Benz, C. [6 ]
Van't Veer, L. J. [7 ]
Esserman, L. [5 ]
Nordenskjold, B. A. [3 ,4 ]
Fornander, T. [1 ]
Stal, O. [3 ,4 ]
Tobin, N. P. [1 ]
Johansson, A. [1 ]
Lindstrom, L. S. [1 ]
机构：
[1] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden
[2] Sahlgrens Acad, Dept Oncol, Gothenburg, Sweden
[3] Linkoping Univ, Dept Biomed & Clin Sci, Linkoping, Sweden
[4] Linkoping Univ, Dept Oncol, Linkoping, Sweden
[5] UCSF Univ Calif San Francisco, Dept Surg, San Francisco, CA USA
[6] UCSF Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[7] UCSF Univ Calif San Francisco, Dept Lab Med, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
基金：
瑞典研究理事会;
关键词：
D O I：
10.1016/j.annonc.2024.08.256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315P
引用
收藏
页码：S346 / S346
页数：1
相关论文
共 50 条
  • [41] High frequency of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen
    Cohen, I
    Beyth, Y
    Shapira, J
    Tepper, R
    Fishman, A
    Cordoba, M
    Bernheim, J
    Yigael, D
    Altaras, MM
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1997, 44 (03) : 200 - 205
  • [42] LONG-TERM HORMONE REPLACEMENT THERAPY AND RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN
    NEWCOMB, PA
    LONGNECKER, MP
    STORER, BE
    MITTENDORF, R
    BARON, J
    CLAPP, RW
    BOGDAN, G
    WILLETT, WC
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (08) : 788 - 795
  • [43] The tumour microenvironment influences long-term tamoxifen treatment response in breast cancer patients
    Romera, P. Camargo
    Romero, M. Rios
    Danielsson, O.
    Dar, H. Akhtar
    Lindstrom, L. S.
    Tobin, N. P.
    ANNALS OF ONCOLOGY, 2024, 35 : S327 - S327
  • [44] Factors of risk for breast cancer influencing postmenopausal long-term hormone replacement therapy
    Chiechi, LM
    Secreto, G
    TUMORI, 2000, 86 (01) : 12 - 16
  • [45] Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial
    Jensen, Maj-Britt
    Krarup, Jens Fabricius
    Palshof, Torben
    Mouridsen, Henning T.
    Ejlertsen, Bent
    ACTA ONCOLOGICA, 2018, 57 (01) : 26 - 30
  • [46] TAMOXIFEN AND BONE METABOLISM IN POSTMENOPAUSAL LOW-RISK BREAST-CANCER PATIENTS - A RANDOMIZED STUDY
    KRISTENSEN, B
    EJLERTSEN, B
    DALGAARD, P
    LARSEN, L
    HOLMEGAARD, SN
    TRANSBOL, I
    MOURIDSEN, HT
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) : 992 - 997
  • [47] ADDITIONAL BENEFIT OF ENDOCRINE THERAPY TO RT IN POSTMENOPAUSAL PATIENTS WITH LOW-RISK BREAST CANCER
    Barbera, Lisa
    Laws, Alison
    Xu, Yuan
    Quan, May Lynn
    RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S16 - S16
  • [48] Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer
    Rutqvist, Lars E.
    Johansson, Hemming
    ACTA ONCOLOGICA, 2007, 46 (02) : 133 - 145
  • [49] Simple ovarian cysts in postmenopausal patients with breast carcinoma treated with tamoxifen: Long-term follow-up
    Cohen, I
    Potlog-Nahari, C
    Shapira, J
    Yigael, D
    Tepper, R
    RADIOLOGY, 2003, 227 (03) : 844 - 848
  • [50] Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors
    Sestak, Ivana
    Cuzick, Jack
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (05) : 425 - 432
12345